Urology
Volume 61, Issue 4, Supplement 1 , Pages 8-14, April 2003

Sustained efficacy and tolerability of vardenafil, a highly potent selective phosphodiesterase type 5 inhibitor, in men with erectile dysfunction: results of a randomized, double-blind, 26-week placebo-controlled pivotal trial☆

  • Wayne J.G. Hellstrom

      Affiliations

    • Department of Urology, Tulane University Medical Center, New Orleans, Louisiana, USA (WJGH)
    • Corresponding Author InformationReprint requests: Wayne J.G. Hellstrom, MD, Tulane University Medical Center, Department of Urology, 1430 Tulane Avenue, New Orleans, Louisiana 70112, USA.
    • ,
  • Marc Gittelman

      Affiliations

    • South Florida Medical Research, Aventura, Florida, USA (MG)
    • ,
  • Gary Karlin

      Affiliations

    • Lawrenceville Urology, Lawrenceville, New Jersey, USA (GK)
    • ,
  • Thomas Segerson

      Affiliations

    • Bayer Corporation, Pharmaceutical Division, West Haven, Connecticut, USA (TS, MT, TT)
    • ,
  • Marc Thibonnier

      Affiliations

    • Bayer Corporation, Pharmaceutical Division, West Haven, Connecticut, USA (TS, MT, TT)
    • ,
  • Terry Taylor

      Affiliations

    • Bayer Corporation, Pharmaceutical Division, West Haven, Connecticut, USA (TS, MT, TT)
    • ,
  • Harin Padma-Nathan

      Affiliations

    • Male Clinic, Beverly Hills, California, USA (HP-N)
    • ,
  • the Vardenafil Study Group

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

☆ This study was funded by Bayer Corporation, Pharmaceutical DivisionWayne J. G. Hellstrom, Marc Gittelman, Gary Karlin, and Harin Padma-Nathan are study investigators funded by the sponsor.

PII: S0090-4295(03)00115-8

doi:10.1016/S0090-4295(03)00115-8

Urology
Volume 61, Issue 4, Supplement 1 , Pages 8-14, April 2003

Article Tools

* Image Usage & Resolution